Ulotaront
Small molecule
Also known as SEP-363856
Evidence outlook · lead readout
NCT04092686 · Schizophrenia
The lead readout missed its primary endpoint. The grade and rationale below record what the trial was designed to show and what it found.
NCT04092686: This was a randomized, quadruple-masked, placebo-controlled trial with 464 participants and a clinical symptom-score primary endpoint (PANSS). The sponsors report that neither ulotaront dose was statistically better than placebo on the primary endpoint. The 100 mg arm separated from placebo nominally, and the registry lists an adjusted one-sided p of 0.041 for it after Hochberg gatekeeping, but the sponsors do not report this as a significant result.
Also in development:Generalized Anxiety Disorder · Phase 3
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT04072354 NCT04072354 · Schizophrenia The trial randomized 463 participants to two ulotaront doses or placebo and used quadruple masking/double-blind procedures. Its primary clinical symptom endpoint, change in PANSS total score at week 6, was not statistically significant for either dose, so the results provide well-controlled but inconclusive evidence of benefit. Registry: NCT04072354 | 3 | Change From Baseline in PANSS Total Score at Week 6 (Baseline, Week 6) 2023-05-12 | Change From Baseline in PANSS Total Score at Week 6 (Baseline, Week 6): Adults: SEP-363856 50mg -16.9 score on a scale (Standard Error 1.57) | Adults: SEP-363856 75mg -19.6 score on a scale (Standard Error 1.56) vs Adults: Placebo -19.3 score on a scale (Standard Error 1.55) | Partial signal | link ↗ |
View 2 more trials
NCT04092686 NCT04092686 · Schizophrenia This was a randomized, quadruple-masked, placebo-controlled trial with 464 participants and a clinical symptom-score primary endpoint (PANSS). The sponsors report that neither ulotaront dose was statistically better than placebo on the primary endpoint. The 100 mg arm separated from placebo nominally, and the registry lists an adjusted one-sided p of 0.041 for it after Hochberg gatekeeping, but the sponsors do not report this as a significant result. Registry: NCT04092686 | 3 | Change From Baseline in PANSS Total Score at Week 6 (Baseline, Week 6) 2023-06-14 | Change From Baseline in PANSS Total Score at Week 6 (Baseline, Week 6): SEP-363856 75mg -16.4 score on a scale (Standard Error 1.49) | SEP-363856 100mg -18.1 score on a scale (Standard Error 1.5) vs Placebo -14.3 score on a scale (Standard Error 1.47) | Partial signal | link ↗ |
NCT05628103 NCT05628103 · Schizophrenia The study was a single-group, open-label trial with 101 participants and no placebo or active comparator, so it could describe tolerability and retention but could not reliably determine ulotaront’s benefit relative to another treatment. Its primary endpoint was clinical-reason discontinuation, reported as 7.9%, but there was no controlled comparison. Registry: NCT05628103 | 3 | Percentage of Participants Who Discontinued From the Study Due to Clinical Reasons (From the first dose of the study drug up to end of follow up (up to Week 9)) 2024-04-01 | Percentage of Participants Who Discontinued From the Study Due to Clinical Reasons (From the first dose of the study drug up to end of follow up (up to Week 9)): SEP-363856 7.9 percentage of participants (95% CI 2.7 to 13.2) | Weak signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (12)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (2)
What this study did
What this study did
Phase 2 (4)
What this study did
What this study did
What this study did
What this study did
Phase 1 (13)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Competitive landscape
This drug's own stage for Generalized Anxiety Disorder: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Ulotaront: this drug | Phase 3 | Small molecule | TAAR1 (trace amine-associated receptor 1) | not yet graded | No reviewed efficacy summary in this indication | |
| Duloxetine (Cymbalta) | Approved | Small molecule | Serotonin/norepinephrine transporter, Serotonin and norepinephrine transporters (SERT/NET) | not yet graded | No reviewed efficacy summary in this indication | |
| Deulumateperone | Phase 3 | Small molecule | Serotonin 5-HT2A / dopamine D1-D2 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Lysergide Tartrate (LSD) (DT120) | Phase 3 | Small molecule | 5-HT2A receptor | Partial signal | NCT06809595: Primary endpoint, HAM-A change at week 12 (100 µg): -9.8 vs -4.7 with placebo, LS mean difference -5.1 points (p<0.0001) (Definium, 2026-09-14). NCT06741228: Primary endpoint, HAM-A change: -11.6 vs -6.2 with placebo, LS mean difference -5.4 points (p<0.0001) (Definium, 2026-08-12). |
Upcoming events
(4 total)
Covered in the briefing Q4 2026 readouts that matter.
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Ulotaront to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.